Klinische Endpunkte in Real-World-Register-Studien: PRAEGNANT-Netzwerk für Patientinnen mit fortgeschrittenem Mammakarzinom

Background: The therapeutic options for the individual patient with metastatic breast cancer are becoming more and more specific. Evidence for therapeutic recommendations from clinical trials is not available for all treatment situations and patient subgroups. This makes the collection and evaluation of real-world data meaningful. Methods and aims: To provide recommendations for up-to-date treatments and participation in clinical trials for patients with metastatic breast cancer, the Prospective Academic Translational Research Network (PREAGNANT) has been established to optimize the oncological quality of care in the advanced therapeutic setting. The main aim is to systematically record medical care of patients with metastatic breast cancer in real life including the therapeutic effects and side effects of the different treatment strategies, to monitor the quality of life changes during therapy, to identify patients who could participate in a clinical drug study and to enable a targeted therapy based on molecular structures of breast cancer patients. Conclusion: This article presents a summary of the PRAEGNANT network and sheds light on the question of the portability of the various endpoints from clinical trials into the real world treatment situation.